US 12,377,071 B2
Methods of treating conditions related to the S1P1 receptor
Alan Glicklich, La Jolla, CA (US); Maria Matilde Sanchez Kam, Alexandria, VA (US); and William R. Shanahan, Del Mar, CA (US)
Assigned to Arena Pharmaceuticals, Inc., New York, NY (US)
Filed by Arena Pharmaceuticals, Inc., New York, NY (US)
Filed on Jan. 8, 2024, as Appl. No. 18/406,732.
Application 17/235,468 is a division of application No. 15/541,496, granted, now 11,007,175, issued on May 18, 2021, previously published as PCT/US2016/012289, filed on Jan. 6, 2016.
Application 18/406,732 is a continuation of application No. 17/235,468, filed on Apr. 20, 2021, granted, now 11,896,578.
Claims priority of provisional application 62/159,550, filed on May 11, 2015.
Claims priority of provisional application 62/100,362, filed on Jan. 6, 2015.
Prior Publication US 2024/0180870 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/403 (2006.01); A61K 9/48 (2006.01); A61P 3/10 (2006.01); A61P 5/00 (2006.01); A61P 17/06 (2006.01); A61P 17/10 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/403 (2013.01) [A61K 9/4825 (2013.01); A61P 3/10 (2018.01); A61P 5/00 (2018.01); A61P 17/06 (2018.01); A61P 17/10 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61K 9/20 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for treating ulcerative colitis in a human comprising administering to the human (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 2.0 mg of Compound 1.